NeoGenomics Net Interest Income from 2010 to 2026
| NEO Stock | USD 12.32 0.18 1.44% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter 1.3 M | Current Value 960 K | Quarterly Volatility 1.9 M |
Check NeoGenomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeoGenomics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 87.6 M, Interest Expense of 8 M or Selling General Administrative of 272.7 M, as well as many indicators such as Price To Sales Ratio of 0.69, Dividend Yield of 0.0059 or PTB Ratio of 0.51. NeoGenomics financial statements analysis is a perfect complement when working with NeoGenomics Valuation or Volatility modules.
NeoGenomics | Net Interest Income | Build AI portfolio with NeoGenomics Stock |
Evaluating NeoGenomics's Net Interest Income across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into NeoGenomics's fundamental strength.
Latest NeoGenomics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of NeoGenomics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. NeoGenomics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeoGenomics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
NeoGenomics Net Interest Income Regression Statistics
| Arithmetic Mean | (2,907,584) | |
| Coefficient Of Variation | (315.20) | |
| Mean Deviation | 7,373,999 | |
| Median | (6,230,000) | |
| Standard Deviation | 9,164,642 | |
| Sample Variance | 84T | |
| Range | 24.3M | |
| R-Value | 0.87 | |
| Mean Square Error | 21.3T | |
| R-Squared | 0.76 | |
| Slope | 1,584,410 | |
| Total Sum of Squares | 1343.9T |
NeoGenomics Net Interest Income History
About NeoGenomics Financial Statements
NeoGenomics investors utilize fundamental indicators, such as Net Interest Income, to predict how NeoGenomics Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | 13.6 M | 14.3 M |
Pair Trading with NeoGenomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if NeoGenomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NeoGenomics will appreciate offsetting losses from the drop in the long position's value.Moving together with NeoGenomics Stock
Moving against NeoGenomics Stock
| 0.67 | SPI | Spire Healthcare | PairCorr |
| 0.65 | S00 | Spire Healthcare | PairCorr |
| 0.61 | FMS | Fresenius Medical Care | PairCorr |
| 0.5 | CCM | Concord Medical Services | PairCorr |
| 0.47 | REG | Regis Healthcare | PairCorr |
The ability to find closely correlated positions to NeoGenomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace NeoGenomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back NeoGenomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling NeoGenomics to buy it.
The correlation of NeoGenomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as NeoGenomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if NeoGenomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for NeoGenomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of NeoGenomics Correlation against competitors. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Will Health Care Providers & Services sector continue expanding? Could NeoGenomics diversify its offerings? Factors like these will boost the valuation of NeoGenomics. Anticipated expansion of NeoGenomics directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every NeoGenomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.306 | Earnings Share (0.89) | Revenue Per Share | Quarterly Revenue Growth 0.119 | Return On Assets |
Investors evaluate NeoGenomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating NeoGenomics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause NeoGenomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between NeoGenomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding NeoGenomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, NeoGenomics' market price signifies the transaction level at which participants voluntarily complete trades.